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Background:  In the United States, Medicare expenditures for heart failure (HF) exceed those for any other disease, and related 
hospitalizations contribute substantially (60%) to the economic burden of HF. This analysis examined the current HF management patterns 
in Medicare Advantage with Part D (MAPD) patients.
methods:  This retrospective, observational study used a large claims database (Optum Research Database) to identify MAPD patients 
with a first observed claim (1 inpatient or ≥2 outpatient claims) for an HF diagnosis (ICD-9: 428.xx, in any position) during the period of 
January 1, 2007, to June 30, 2013. Patient demographics, use of HF medical devices, HF medications and resource use were assessed.
results:  A total of 127,760 patients met the study criteria; mean follow-up was 22.3 months. In about half (61%) the HF patients, the 
first observed claim was in the inpatient setting. Mean age was 76 years and 48% of patients were men. During the study period, 68.2%, 
58.9% and 68.6% of patients used β blockers, angiotensin-converting enzyme (ACE) inhibitors and diuretics, respectively. Aldosterone 
antagonists, digitalis and inotropes were each used by about 15% of patients. During the study period, 10% of patients had a cardiac 
resynchronization therapy device and 5.6% had an implantable cardioverter defibrillator. Patients were hospitalized on average 1.13 
times for HF during the 12 months after the first observed claim (denominator included patients who were enrolled for a year or died). The 
estimated associated average cost for each hospitalization was $19,500 (USD). The median duration of the first HF hospitalization was 6 
days.
conclusion:  Despite current HF management patterns, more efforts are needed to reduce the burden of HF, as measured by resource 
use that includes hospitalization, on a Medicare Advantage population.
